🎉 #Gate Alpha 第三届积分狂欢节 & ES Launchpool# 聯合推廣任務上線!
本次活動總獎池:1,250 枚 ES
任務目標:推廣 Eclipse($ES)Launchpool 和 Alpha 第11期 $ES 專場
📄 詳情參考:
Launchpool 公告:https://www.gate.com/zh/announcements/article/46134
Alpha 第11期公告:https://www.gate.com/zh/announcements/article/46137
🧩【任務內容】
請圍繞 Launchpool 和 Alpha 第11期 活動進行內容創作,並曬出參與截圖。
📸【參與方式】
1️⃣ 帶上Tag #Gate Alpha 第三届积分狂欢节 & ES Launchpool# 發帖
2️⃣ 曬出以下任一截圖:
Launchpool 質押截圖(BTC / ETH / ES)
Alpha 交易頁面截圖(交易 ES)
3️⃣ 發布圖文內容,可參考以下方向(≥60字):
簡介 ES/Eclipse 項目亮點、代幣機制等基本信息
分享你對 ES 項目的觀點、前景判斷、挖礦體驗等
分析 Launchpool 挖礦 或 Alpha 積分玩法的策略和收益對比
🎁【獎勵說明】
評選內容質量最優的 10 位 Launchpool/Gate
Sonnet
Key Insights:
Sonnet BioTherapeutics has signed a definitive agreement to merge with Rorschach I LLC, forming Hyperliquid Strategies Inc. The $888 million transaction will create a public crypto treasury company holding the HYPE token. Upon closing, the company expects to trade on Nasdaq under a new ticker symbol.
Strategic Shift Toward Digital Asset Holdings
The transaction includes $583 million in HYPE tokens and $305 million in committed cash investment. The combined reserves will position Hyperliquid Strategies Inc (HSI) as the largest U.S.-listed holder of the Hyperliquid Layer-1 blockchain token. According to Sonnet’s SEC filing, the valuation is based on HYPE’s spot price prior to the agreement.
Sonnet will become a wholly owned subsidiary of HSI and continue developing key assets such as SON-1010. It will also explore divestitures of non-core assets as part of the new treasury strategy. The transaction is subject to shareholder approval and customary regulatory closing conditions.
Post-Merger Operations and Shareholder Impact
At completion, Bob Diamond will serve as Chairman and David Schamis will become CEO of the new entity. The board will include Eric Rosengren, former Boston Fed President, and two current Sonnet independent directors. HSI also plans to appoint a new Chief Financial Officer to oversee treasury operations.
The deal includes a private placement of $5.5 million in preferred stock and warrants, closing on July 14, 2025. Convertible notes worth $2 million sold in June will convert into this offering. Net proceeds will fund biotech operations and business combination expenses.
After closing, existing Rorschach and new investors will hold about 98.8% of HSI, with Sonnet shareholders holding 1.2%. Lucid Capital Markets has provided a fairness opinion, and Chardan is serving as the sole placement agent. Legal counsel includes Greenberg Traurig for Rorschach and Lowenstein Sandler for Sonnet.
| | | --- | | DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing. |